Practical perspectives on pharmaceutical quality, advanced therapies and regulatory expectations.
Jon brings experience from quality leadership, manufacturing support and independent consultancy to technical presentations and professional discussion.
Enquire about a speaking engagementSelected conference presentations and webinars. The 2024 engagements were joint presentations with Alfred Penfold of PM Group, during Jon’s tenure as Managing Director for Quality at Cell and Gene Therapy Catapult. Historical affiliations reflect the time of each event.
18 June 2025
A UK-focused contribution to an international programme exploring regulatory and operational issues in cell and gene therapy. The programme brought together perspectives from several jurisdictions alongside quality oversight and product-release topics.
View organiser programme ↗13 May 2025
A joint session examining differing regulatory approaches and their practical significance for advanced therapy manufacturing. Topics included GMP and tissue-practice boundaries, viral-safety considerations and point-of-care manufacture.
Read the published session summary ↗21 November 2024
A joint presentation on accommodating different ATMP modalities within the same facility, connecting segregation and contamination control with the responsibilities and interactions of pharmaceutical quality systems. Presented during Jon’s tenure as Managing Director for Quality at Cell and Gene Therapy Catapult.
View event listing ↗
14 October 2024
A joint presentation connecting biological and chemical risk assessment with facility segregation, regulatory engagement and organisational readiness. Drawing on shared-facility experience, the session covered quality-system interfaces, inspection learning, collaborator onboarding and manufacturing-team training.
Read the published session summary ↗11 September 2024
A joint presentation bringing together multi-modality risk assessment, facility segregation and shared-facility quality governance. The material explored regulatory engagement and inspection learning alongside collaborator onboarding, workforce training and the development of operational readiness.
18 April 2024
A joint presentation examining how biological and chemical risk profiles inform the segregation of ATMP modalities and the selection of facility controls. Topics included shared-facility quality responsibilities, quality agreements, communication between pharmaceutical quality systems and lessons from regulatory engagement and inspections.
View event listing ↗
Potential subjects for discussion include contamination control, ATMP quality and regulatory considerations, inspection readiness, shared-facility operating models and practical GMP decision-making. Content and format can be discussed against the needs of your event.
Discuss your eventExplore specialist training